Clinical Trials in Zhangjiagang, China
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Hepatocellular Carcinoma
AstraZeneca210 enrolled32 locationsNCT05557838
Recruiting
PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study
Cardiovascular DiseaseType 2 Diabetes Mellitus
Beijing Anzhen Hospital3,000 enrolled27 locationsNCT06336239